Improving the safety of cell therapy products by suicide gene transfer
about
CAR models: next-generation CAR modifications for enhanced T-cell functionNew Strategies for the Treatment of Solid Tumors with CAR-T CellsImmune targeting of cancer stem cells in gastrointestinal oncologyThe Application of Natural Killer Cell Immunotherapy for the Treatment of CancerNovel immunotherapies in lymphoid malignanciesAdoptive T-cell therapy for cancer: The era of engineered T cellsCAR T Cell Therapy: A Game Changer in Cancer TreatmentAdvantages and applications of CAR-expressing natural killer cellsEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsGenetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.Editorial: Improving the safety of cell therapy products by suicide gene transfer.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.New development in CAR-T cell therapy.New approaches for the immunotherapy of acute myeloid leukemia.Synthetic biology in cell-based cancer immunotherapy.NK cell-based cancer immunotherapy: from basic biology to clinical application.Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Chimeric antigen receptor engineered stem cells: a novel HIV therapy.Modeling Natural Killer Cell Targeted Immunotherapies.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelTherapeutic Gene Editing Safety and Specificity.Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase.T Cell Receptor Profiling in Type 1 Diabetes.Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes.Human c-SRC kinase (CSK) overexpression makes T cells dummy.Distinct Responses of Stem Cells to Telomere Uncapping-A Potential Strategy to Improve the Safety of Cell Therapy.Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease.
P2860
Q26745600-CE5B0F9B-0851-44F1-BB2D-85A9EB16179CQ26748500-30DAE193-1035-4900-85B9-F79041668412Q26749015-F9075630-4AD8-4666-8589-B014CFA5A3DDQ26774678-AD4FA922-6A0E-4474-AD96-1EE6246D068DQ26777394-6E6B50FB-17F1-4AE2-B412-FA7110898BAEQ26800611-653FDDD1-6BA8-42E5-8DD9-2CE37E939E5BQ26822769-E5CA87BE-796B-4B3C-87D8-994D811833ECQ28080875-F483CE2B-CDF5-4A7A-A33A-5576EE881A48Q33833475-9C14111A-82D1-442A-857B-58A380CFC2B1Q35711209-B0E0C3AC-E710-44EF-8F8B-B2CC054508CDQ35992678-9A0A662C-1B40-4D7D-AC1A-6060007B4ABBQ37559401-FBEE46CD-3B24-4958-8752-2A1C7E816AB3Q37658246-0A65952D-D3C0-4D38-B4CC-AEDD63BD2A43Q38482206-197122A0-0168-48F9-90C4-05B304DA628FQ38531361-6E81A3BC-59BC-42EF-A4FE-048A771E11C3Q38640489-7E26E36A-3D91-407A-A98B-A75C74A0E28FQ38666862-4862CF80-B0CD-4A78-9680-B21CC37EA567Q38773361-47742292-770D-4969-86B8-83B6FAD5EB35Q38913549-A14A4F28-06FB-4717-83B8-DE816AB6B42EQ39161011-9B28838D-F0E9-4AF4-9850-FF3B723BF9A6Q39208504-9C6149A4-E1DC-4C50-BC7C-734221096E25Q39239278-9A9F3D5C-BEC3-41FC-9DD6-47519B7EE930Q39249589-D80D3945-D78E-4A40-999F-A7C884D7AD9FQ40045823-A229113B-606B-45BD-9322-AE5E77C966FAQ40314122-8904C5B4-8F73-4E5F-B8B2-C85BE2FDC133Q40418970-073F9841-92DA-4C97-9AD8-F7EDCC23A65DQ42374922-3BC54A7F-2A18-4FE0-92AE-9E1898E1609EQ46453590-5CC17F45-9EB2-4A9B-90EA-172310A6A87EQ48105379-A7101591-B327-4563-B5B7-0D1768D0F5DAQ48200984-950F74C1-4D07-4D79-83E1-5E2C70812246Q55216327-9426ECAC-B5D7-4616-919E-1C7499D59528Q55245977-A77CCA81-DED6-4FAD-9861-D097C96F543D
P2860
Improving the safety of cell therapy products by suicide gene transfer
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Improving the safety of cell therapy products by suicide gene transfer
@ast
Improving the safety of cell therapy products by suicide gene transfer
@en
Improving the safety of cell therapy products by suicide gene transfer
@nl
type
label
Improving the safety of cell therapy products by suicide gene transfer
@ast
Improving the safety of cell therapy products by suicide gene transfer
@en
Improving the safety of cell therapy products by suicide gene transfer
@nl
prefLabel
Improving the safety of cell therapy products by suicide gene transfer
@ast
Improving the safety of cell therapy products by suicide gene transfer
@en
Improving the safety of cell therapy products by suicide gene transfer
@nl
P2093
P2860
P356
P1476
Improving the safety of cell therapy products by suicide gene transfer
@en
P2093
Antonio Di Stasi
Benjamin S Jones
Frederick Goldman
Lawrence S Lamb
P2860
P356
10.3389/FPHAR.2014.00254
P577
2014-11-27T00:00:00Z